Skip to main content

Table 3 Proportion of patients with incomplete follow-up.

From: The effect of varying analytical methods on estimates of anti-malarial clinical efficacy

  Africa Thailand Overall
Unadjusted Analysis 7619 7790 15,409
Interrupted follow-up a 360 (4.7%) 1117 (14.3%) 1477 (9.6%)
Non-falciparum new infections 40 (0.5%) 1120 (14.4%) 1160 (7.5%)
Overall 400 (5.3%) 2237 (28.7%) 2637 (17.1%)
Adjusted Analysis b 7619 5813 13,432
Interrupted follow-up a 360 (4.7%) 673 (11.6%) 1033 (7.7%)
Non-falciparum new infections 40 (0.5%) 1023 (17.6%) 1063 (7.9%)
P. falciparum new infections 1864 (24.5%) 323 (5.6%) 2187 (16.3%)
Unsuccessful genotyping 107 (1.4%) 99 (1.7%) 206 (1.5%)
Overall 2371 (31.1%) 2118 (36.4%) 4489 (33.4%)
  1. a Includes all patients with interrupted follow-up (outcomes 13–20 in table 1)
  2. b Excludes 1977 Thai patients (from 5 studies with 8 treatment arms) in which genotyping was not attempted